Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes

Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy

(2017) Ahmed A Hasan et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy

(2017) Xiaojun Ren et al.   PHARMACOLOGY

DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control

(2016) Eun Ju Bae   ARCHIVES OF PHARMACAL RESEARCH

Podocytes: the Weakest Link in Diabetic Kidney Disease?

(2016) Jamie S. Lin et al.   Current Diabetes Reports

Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE)

(2016) Tomoya Mita et al.   DIABETES CARE

Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release

(2016) Tania Romacho et al.   JOURNAL OF HYPERTENSION

Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes

(2016) Ming Ji et al.   MEDICINE

Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus

(2016) Minhua Fan et al.   MEDICINE

Metabolomics in diabetic complications

(2016) Laura A. Filla et al.   Molecular BioSystems

Combination of Sitagliptin and Insulin against Type 2 Diabetes Mellitus with Neuropathy in Rats: Neuroprotection and Role of Oxidative and Inflammation Stress

(2016) Mohamed Elsayed Kelany et al.   PHARMACOLOGY

DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid

(2016) Jun Shirakawa et al.   Diabetology & Metabolic Syndrome

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial

(2016) Yaeko Kondo et al.   Diabetology & Metabolic Syndrome

Effect of GLP-1 Receptor Activation on Offspring Kidney Health in a Rat Model of Maternal Obesity

(2016) Sarah J. Glastras et al.   Scientific Reports

Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets

(2016) Manel Mata-Cases et al.   Journal of Diabetes

Incretin-Based Therapy for Prevention of Diabetic Vascular Complications

(2016) Akira Mima   Journal of Diabetes Research

A Narrative Review of Diabetes Intervention Studies to Explore Diabetes Care Opportunities for Pharmacists

(2016) Shamala Ayadurai et al.   Journal of Diabetes Research

Endothelial Progenitor Cells in Diabetic Microvascular Complications: Friends or Foes?

(2016) Cai-Guo Yu et al.   Stem Cells International

Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure

(2016) Daniel F. Arruda-Junior et al.   Frontiers in Physiology

The Incidence of End-Stage Renal Disease in the Diabetic (Compared to the Non-Diabetic) Population: A Systematic Review

(2016) Maria Narres et al.   PLoS One

1. Strategies for Improving Care

(2015)   DIABETES CARE

Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure

(2015) Thiago Salles et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats

(2015) Yu-Sheng Liu et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition

(2015) Sen Shi et al.   KIDNEY INTERNATIONAL

Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis

(2015) Takanori Matsui et al.   LABORATORY INVESTIGATION

Molecular Events Linking Oxidative Stress and Inflammation to Insulin Resistance andβ-Cell Dysfunction

(2015) Kevin Noel Keane et al.   Oxidative Medicine and Cellular Longevity

Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats

(2015) Sezin Karabulut et al.   Pharmacological Reports

Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects

(2015) Radwan H. Ahmed et al.   PLoS One

Mechanisms Linking Inflammation to Insulin Resistance

(2015) Li Chen et al.   International Journal of Endocrinology

Dynamic pathology of islet endocrine cells in type 2 diabetes: β-Cell growth, death, regeneration and their clinical implications

(2015) Soroku Yagihashi et al.   Journal of Diabetes Investigation

Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?

(2015) Wellington Santana da Silva Júnior et al.   Biomed Research International

NADPH Oxidase-Induced NALP3 Inflammasome Activation Is Driven by Thioredoxin-Interacting Protein Which Contributes to Podocyte Injury in Hyperglycemia

(2015) Pan Gao et al.   Journal of Diabetes Research

The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?

(2015) Ricardo Godinho et al.   Journal of Diabetes Research

Inflammatory Cytokines in Diabetic Nephropathy

(2015) Javier Donate-Correa et al.   Journal of Diabetes Research

The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease

(2015) Usha Panchapakesan et al.   Frontiers in Immunology

DPP4 in diabetes

(2015) Diana Röhrborn   Frontiers in Immunology

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

(2015) Jose Górriz et al.   Journal of Clinical Medicine

Dipeptidyl peptidase-IV inhibition prevents blood–retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats

(2014) Andreia Gonçalves et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms

(2014) Yanmei Zeng et al.   Cardiovascular Diabetology

Chronic Dipeptidyl Peptidase-4 Inhibition With Sitagliptin Is Associated With Sustained Protection Against Ischemic Left Ventricular Dysfunction in a Pilot Study of Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

(2014) Liam M. McCormick et al.   Circulation-Cardiovascular Imaging

Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat

(2014) Peter Vavrinec et al.   Current Vascular Pharmacology

The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications

(2014) Angelo Avogaro et al.   DIABETES CARE

Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

(2014) Greg L. Plosker   DRUGS

Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors

(2014) Erin E. Mulvihill et al.   ENDOCRINE REVIEWS

Prevention of Obesity-Induced Renal Injury in Male Mice by DPP4 Inhibition

(2014) Ravi Nistala et al.   ENDOCRINOLOGY

Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis

(2014) S. Nakashima et al.   HORMONE AND METABOLIC RESEARCH

The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Protects against Dyslipidemia-Related Kidney Injury in Apolipoprotein E Knockout Mice

(2014) Jingjing Li et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease

(2014) Un Jung et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The potential for renoprotection with incretin-based drugs

(2014) Tetsuhiro Tanaka et al.   KIDNEY INTERNATIONAL

Advanced Glycation End Products and Diabetic Complications

(2014) Varun Parkash Singh et al.   KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY

Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction

(2014) Hye Sook Min et al.   LABORATORY INVESTIGATION

Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals

(2014) Catarina Marques et al.   MEDIATORS OF INFLAMMATION

DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat

(2014) Ravi Nistala et al.   Obesity

Oxidative Stress and Metabolic Pathologies: From an Adipocentric Point of View

(2014) Soazig Le Lay et al.   Oxidative Medicine and Cellular Longevity

Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

(2014) Belén Picatoste et al.   PLoS One

Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties

(2014) Cristina Mega et al.   Diabetology & Metabolic Syndrome

Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials

(2014) K. Esposito et al.   BMJ Open

Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate 西格列汀通过降低2型糖尿病患者的血压以及估算的肾小球滤过率来减少尿白蛋白/肌酐的比值

(2014) Isao Kawasaki et al.   Journal of Diabetes

Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes

(2013) Ryo Kodera et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats

(2013) Nattayaporn Apaijai et al.   BRITISH JOURNAL OF PHARMACOLOGY

Physiology and pathophysiology of incretins in the kidney

(2013) Karoline von Websky et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Relationship of Glycated Albumin to Blood Glucose and HbA1c Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study

(2013) D. M. Nathan et al.   DIABETES

Variations in Inflammatory Biomarkers Following the Addition of Sitagliptin in Patients with Type 2 Diabetes not Controlled with Metformin

(2013) Giuseppe Derosa et al.   INTERNAL MEDICINE

Insulin signaling, resistance, and metabolic syndrome: insights from mouse models into disease mechanisms

(2013) Shaodong Guo   JOURNAL OF ENDOCRINOLOGY

c-Abl mediates angiotensin II-induced apoptosis in podocytes

(2013) Xinghua Chen et al.   JOURNAL OF MOLECULAR HISTOLOGY

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

(2013) Steven E Kahn et al.   LANCET

The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?

(2013) Marcel H. A. Muskiet et al.   Nature Reviews Nephrology

DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes

(2013) Annayya Aroor et al.   CardioRenal Medicine

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

(2013) Samuel S. Engel et al.   Diabetes Therapy

Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis

(2013) Keizo Kanasaki et al.   Frontiers in Endocrinology

Beta Cell Dysfunction and Insulin Resistance

(2013) Marlon E. Cerf   Frontiers in Endocrinology

Both sitagliptin analogue & pioglitazone preserve the β-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice

(2012) Jin-A Yeom et al.   BMB Reports

Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition

(2012) Swenja Kröller-Schön et al.   CARDIOVASCULAR RESEARCH

Recent advances in incretin-based therapies

(2012) David Russell-Jones et al.   CLINICAL ENDOCRINOLOGY

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

(2012) J. C. Arjona Ferreira et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

(2012) Limei Liu et al.   HYPERTENSION

Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin

(2012) M K Piya et al.   JOURNAL OF ENDOCRINOLOGY

Renal and Cardiac Effects of DPP-4 Inhibitors – from Preclinical Development to Clinical Research

(2012) Berthold Hocher et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level

(2012) Yuji Ishibashi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases

(2012) Hari Hendarto et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients

(2012) Noriko Satoh-Asahara et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Lifestyle Change and Mobility in Obese Adults with Type 2 Diabetes

(2012) W. Jack Rejeski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity

(2012) Yumei Wang et al.   PLoS One

Urinary Platelet-Derived Growth Factor-BB as an Early Marker of Nephropathy in Patients with Type 2 Diabetes: An Egyptian Study

(2012) Sahar Saad-El-Din Bessa et al.   RENAL FAILURE

Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries

(2011) Veerle Matheeussen et al.   BIOLOGICAL CHEMISTRY

Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice

(2011) J. Shirakawa et al.   DIABETES

Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes

(2011) P. C. M. van Poppel et al.   DIABETES CARE

Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence

(2011) R. E. van Genugten et al.   DIABETES OBESITY & METABOLISM

Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model

(2011) A. Gonçalves et al.   DIABETES OBESITY & METABOLISM

Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice

(2011) Y. Takeda et al.   DIABETOLOGIA

Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)

(2011) Cristina Mega et al.   Experimental Diabetes Research

Tubular biomarkers to assess progression of diabetic nephropathy

(2011) Gianfranco Tramonti et al.   KIDNEY INTERNATIONAL

Glucagon-like peptide–1 suppresses advanced glycation end product–induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing advanced glycation end product receptor level

(2011) Yuji Ishibashi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Diabetic neuropathy: cellular mechanisms as therapeutic targets

(2011) Andrea M. Vincent et al.   Nature Reviews Neurology

The Role of Overweight and Obesity in the Cardiorenal Syndrome

(2011) James R. Sowers et al.   CardioRenal Medicine

Understanding the Cardiovascular Effects of Incretin

(2011) Ji Sung Yoon et al.   Diabetes & Metabolism Journal

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice

(2010) A. D. Dobrian et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease

(2010) Philip A. Read et al.   Circulation-Cardiovascular Imaging

The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1 

(2010) G. P. Fadini et al.   DIABETES CARE

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

(2010) A. J. Scheen   DIABETES OBESITY & METABOLISM

Tribbles homologue 3 (TRIB3) and the insulin-resistance genes in type 2 diabetes

(2010) F. Beguinot   DIABETOLOGIA

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats

(2010) Bruna PM Pacheco et al.   JOURNAL OF HYPERTENSION

Pathologic Classification of Diabetic Nephropathy

(2010) T. W. C. Tervaert et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

New paradigms in cell death in human diabetic nephropathy

(2010) Maria-Dolores Sanchez-Niño et al.   KIDNEY INTERNATIONAL

Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)

(2010) Liliana Ferreira et al.   MEDIATORS OF INFLAMMATION

Oxidative stress in early diabetic nephropathy: fueling the fire

(2010) Dhruv K. Singh et al.   Nature Reviews Endocrinology

Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes

(2010) Jitendra Vaghasiya et al.   REGULATORY PEPTIDES

The role of reactive oxygen species in apoptosis of the diabetic kidney

(2009) F. A. D. T. G. Wagener et al.   APOPTOSIS

Effect of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor (Vildagliptin) on Peripheral Nerves in Streptozotocin-induced Diabetic Rats

(2009) Heung Yong Jin et al.   ARCHIVES OF MEDICAL RESEARCH

Pathogenic perspectives for the role of inflammation in diabetic nephropathy

(2009) Antonio Rivero et al.   CLINICAL SCIENCE

Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin

(2009) A. V. Matveyenko et al.   DIABETES

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

(2009) J. E. Gerich   DIABETIC MEDICINE

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

(2009) James Mu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Differential Importance of Glucose-Dependent Insulinotropic Polypeptide vs Glucagon-Like Peptide 1 Receptor Signaling for Beta Cell Survival in Mice

(2009) Adriano Maida et al.   GASTROENTEROLOGY

Exendin-4 Promotes Liver Cell Proliferation and Enhances thePDX-1-induced Liver to Pancreas Transdifferentiation Process

(2009) Vered Aviv et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Impaired Tubular Uptake Explains Albuminuria in Early Diabetic Nephropathy

(2009) L. M. Russo et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

(2009) E.J. Verspohl   PHARMACOLOGY & THERAPEUTICS

Reduced levels of cyclic AMP contribute to the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive ratsThis article is one of a selection of papers published in the special issue Bridging the Gap: Where Progress in Cardiovascular and Neurophysiologic Research Meet.

(2008) Soumya Saha et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Dephosphorylation of Translation Initiation Factor 2α Enhances Glucose Tolerance and Attenuates Hepatosteatosis in Mice

(2008) Seiichi Oyadomari et al.   Cell Metabolism

New Drugs for the Treatment of Diabetes

(2008) Silvio E. Inzucchi et al.   CIRCULATION

Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes

(2008) J. M. Forbes et al.   DIABETES

Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes

(2008) J.-F. Gautier et al.   DIABETES & METABOLISM

Islet Inflammation in Type 2 Diabetes: From metabolic stress to therapy

(2008) M. Y. Donath et al.   DIABETES CARE

Novel functions of the CD34 family

(2008) J. S. Nielsen et al.   JOURNAL OF CELL SCIENCE

TheTRIB3Q84R Polymorphism and Risk of Early-Onset Type 2 Diabetes

(2008) Sabrina Prudente et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Role of Inflammatory Cytokines in Diabetic Nephropathy

(2008) J. F. Navarro-Gonzalez et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY